Swords R - Search Results

1

Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.

Giles FJ, O'Dwyer M, Swords R. Giles FJ, et al. Among authors: swords r. Leukemia. 2009 Oct;23(10):1698-707. doi: 10.1038/leu.2009.111. Epub 2009 May 28. Leukemia. 2009. PMID: 19474800 Review.

2

MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.

Giles FJ, Swords RT, Nagler A, Hochhaus A, Ottmann OG, Rizzieri DA, Talpaz M, Clark J, Watson P, Xiao A, Zhao B, Bergstrom D, Le Coutre PD, Freedman SJ, Cortes JE. Giles FJ, et al. Among authors: swords rt. Leukemia. 2013 Jan;27(1):113-7. doi: 10.1038/leu.2012.186. Epub 2012 Jul 9. Leukemia. 2013. PMID: 22772060 Clinical Trial.

3

Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia.

Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E, Oberheu K, Padmanabhan S, O'Dwyer M, Nawrocki ST, Giles FJ, Carew JS. Swords RT, et al. Blood. 2010 May 6;115(18):3796-800. doi: 10.1182/blood-2009-11-254862. Epub 2010 Mar 4. Blood. 2010. PMID: 20203261 Free article.

4

Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors.

Kelly K, Swords R, Mahalingam D, Padmanabhan S, Giles FJ. Kelly K, et al. Among authors: swords r. Target Oncol. 2009 Apr;4(2):99-105. doi: 10.1007/s11523-009-0110-4. Epub 2009 Apr 21. Target Oncol. 2009. PMID: 19381453 Review.

5

Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia.

Swords R, Alvarado Y, Cortes J, Giles FJ. Swords R, et al. Curr Hematol Malig Rep. 2007 May;2(2):83-8. doi: 10.1007/s11899-007-0012-4. Curr Hematol Malig Rep. 2007. PMID: 20425355 Review.

6

Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents.

Kelly K, Swords R, Mahalingam D, Giles FJ. Kelly K, et al. Among authors: swords r. Leuk Lymphoma. 2010 Aug;51(8):1399-413. doi: 10.3109/10428194.2010.491135. Leuk Lymphoma. 2010. PMID: 20528247 Review.

7

Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia.

Giles F, Mahon FX, Gjertsen B, Swords R, Labar B, Turkina A, Rosti G. Giles F, et al. Among authors: swords r. Eur J Clin Invest. 2012 Sep;42(9):1016-26. doi: 10.1111/j.1365-2362.2012.02675.x. Epub 2012 May 1. Eur J Clin Invest. 2012. PMID: 22548456 Review.

8

Nilotinib 300 mg BID as frontline treatment of CML: prospective analysis of the Xpert BCR-ABL monitor system and significance of 3-month molecular response.

O'Dwyer ME, Swords R, Nagler A, McMullin MF, le Coutre PD, Langabeer SE, Alvarez-Iglesias A, Fan H, Woodman RC, Giles FJ, Conneally E. O'Dwyer ME, et al. Among authors: swords r. Leuk Res. 2014 Mar;38(3):310-5. doi: 10.1016/j.leukres.2013.11.016. Epub 2013 Dec 1. Leuk Res. 2014. PMID: 24333114 Clinical Trial.

9

Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia.

Swords R, Freeman C, Giles F. Swords R, et al. Leukemia. 2012 Oct;26(10):2176-85. doi: 10.1038/leu.2012.114. Epub 2012 Apr 27. Leukemia. 2012. PMID: 22614177 Review.

10

Emerging drugs in the treatment of pancreatic cancer.

Mahalingam D, Kelly KR, Swords RT, Carew J, Nawrocki ST, Giles FJ. Mahalingam D, et al. Among authors: swords rt. Expert Opin Emerg Drugs. 2009 Jun;14(2):311-28. doi: 10.1517/14728210902972502. Expert Opin Emerg Drugs. 2009. PMID: 19466902 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

108 results

Search Page